Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2019 Jun 21;18(9):1615–1627. doi: 10.1158/1535-7163.MCT-18-0706

Table 1.

Leukemic cell lines used in this study

Human
leukemia cell
line
P53
response
to
irradiation
P53 status BCR-ABL
status
Source
ATCC
JM1 (B-ALL) Yes Wild type None CRL-10423
SB (B-ALL) Yes Wild type None CCL-120
MUTZ5 Yes Wild type Ph-like
MHH-CALL4 Yes Wild type Ph-like
Nalm6 (B-ALL) Yes Wild type Ph+ CRL-3273
Nalm1(B-ALL) NA Wild type Ph+ CRL-1567
Sup B15(B-ALL) NA Wild type Ph+ CRL-1929
CEM(T-ALL) No Multiple mutation NA CCL-119
SupT1(T-ALL) Yes Wild type NA CRL-1942
Molt4(T-ALL) Yes Wild type NA CRL-1582
Jurkat(T-ALL) Weaker Multiple mutation NA TIB-152
HL60 (AML) No Null NA CCL-240
Reh Yes Wild type NA CRL-8286
HS5 NA Bone marrow fibroblast NA CRL-11882

Note: Finger printed positive cell lines with mycoplasma negative status were used within 20 passages from thawing. P53 protein expression in response to gamma-irradiation (800 rads) was confirmed by using cytometry (L.S. Golfman; unpublished observation). Wild-type p53 status was verified by sequencing or querying in the COSMIC database and/or searching the literature. NA: not applicable for irradiation/BCR-ABL studies performed.